Business Context and Reporting Period
X4 Pharmaceuticals, Inc. (XFOR) filed this Form 8-K on November 14, 2019, to report the entry into a material definitive agreement. The Company is an emerging growth company incorporated in Delaware with its principal executive offices in Cambridge, Massachusetts.
Key Financial Metrics and Obligations
This filing details a new lease agreement rather than operational financial results. Key financial terms include:
- Security Deposit: $1.1 million required in the form of a letter of credit.
- Tenant Improvement Contribution: Landlord contribution of up to $1.8 million.
- Rent Commencement: May 11, 2020, following a 180-day rent-free period.
- Base Rent Rate: $35.00 per rentable square foot per year (annualized), subject to scheduled increases.
- Lease Term: 84 months from execution, with an option to renew for an additional five years.
Material Changes
The Company entered into a lease for approximately 28,000 square feet of office space at 61 North Beacon Street, Allston, Massachusetts. This new lease will replace the current headquarters lease at 955 Massachusetts Avenue, Cambridge, which expires in July 2022. The Company intends to move into the new premises in mid-2020.
Outlook and Risks
The filing notes that the rent-free period and commencement of payments are subject to the timely completion of construction of the Premises. The Company retains the right to sublease the premises subject to landlord consent. No specific guidance on revenue, profit, or cash flow was provided in this filing.
Investor Verification Checklist
- Verify the Company's current cash position to ensure it can fund the $1.1 million letter of credit requirement.
- Monitor the construction timeline to confirm the May 11, 2020, rent commencement date.
- Review the full text of the Lease agreement when filed as an exhibit to the 2019 Form 10-K for detailed operating expense obligations.
- Assess the impact of the new lease on future operating expenses compared to the expiring Cambridge lease.